Naoki Inui
YOU?
Author Swipe
View article: Antifibrotic therapy in familial idiopathic pulmonary fibrosis: a comparative cohort study
Antifibrotic therapy in familial idiopathic pulmonary fibrosis: a comparative cohort study Open
Before the introduction of antifibrotic therapy, patients with familial pulmonary fibrosis (FPF) were reported to have a higher mortality risk than those with sporadic disease. Genetic predisposition plays an important role in the developm…
View article: Discovery of Pyrazole-Based Positron Emission Tomography Agent that Maps Histone Deacetylase 6 (HDAC6) in the Nonhuman Primate Brain
Discovery of Pyrazole-Based Positron Emission Tomography Agent that Maps Histone Deacetylase 6 (HDAC6) in the Nonhuman Primate Brain Open
Histone deacetylase 6 (HDAC6) is a crucial target for the development of pharmaceuticals used in the treatment of neurodegenerative disorders. Here, we identified 16a as a candidate of positron emission tomography (PET) tracer for HDAC6 im…
View article: Risk stratification of acute exacerbations by autoantibodies in patients with idiopathic interstitial pneumonia
Risk stratification of acute exacerbations by autoantibodies in patients with idiopathic interstitial pneumonia Open
Although acute exacerbation of idiopathic interstitial pneumonia (AE-IIP) is a critical event, the detailed features of connective tissue diseases (CTD) that affect the incidence of AE-IIP have not been fully elucidated. This study aimed t…
View article: Efficacy of Low-Voltage-Area Ablation Is Enhanced in Patients With Advanced Left Atrial Enlargement: A Subanalysis of the SUPPRESS-AF Trial
Efficacy of Low-Voltage-Area Ablation Is Enhanced in Patients With Advanced Left Atrial Enlargement: A Subanalysis of the SUPPRESS-AF Trial Open
BACKGROUND: In the randomized controlled SUPPRESS-AF trial (Efficacy and Safety of Left Atrial Low-voltage Area Guided Ablation for Recurrence Prevention Compared to Pulmonary Vein Isolation Alone in Patients with Persistent Atrial Fibrill…
View article: Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting
Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting Open
Improved CINV prevention was observed with NEPA-based regimens, particularly during Days 3-5, highlighting its potential for managing prolonged nausea and vomiting associated with emerging anticancer targeted therapies.
View article: PAI-1 Inhibitor TM5441 Attenuates Emphysema and Airway Inflammation in a Murine Model of Chronic Obstructive Pulmonary Disease
PAI-1 Inhibitor TM5441 Attenuates Emphysema and Airway Inflammation in a Murine Model of Chronic Obstructive Pulmonary Disease Open
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide, primarily driven by chronic airway inflammation due to cigarette smoke exposure. Despite its burden, however, current anti-inflammatory the…
View article: Analysis of the relationship between bronchoalveolar lavage lymphocyte fraction and detailed autoimmune features in patients with idiopathic interstitial pneumonia
Analysis of the relationship between bronchoalveolar lavage lymphocyte fraction and detailed autoimmune features in patients with idiopathic interstitial pneumonia Open
Bronchoalveolar lavage (BAL) is crucial for the diagnosis of interstitial lung disease (ILD). Although BAL lymphocytosis is found in patients with connective tissue disease (CTD)-related ILD, the effects of CTD-associated features on BAL l…
View article: Alveolar Sarcoidosis Mimicking Idiopathic Interstitial Pneumonia Without Mediastinal Lymphadenopathy
Alveolar Sarcoidosis Mimicking Idiopathic Interstitial Pneumonia Without Mediastinal Lymphadenopathy Open
We present a case of alveolar sarcoidosis showing lower lobe‐predominant areas of airspace consolidation and ground‐glass attenuation on HRCT , mimicking idiopathic interstitial pneumonia ( IIP ) with spontaneous wandering. Mediastinal lym…
View article: Pulmonary Hyalinizing Granuloma With Favourable and Longitudinal Treatment Response
Pulmonary Hyalinizing Granuloma With Favourable and Longitudinal Treatment Response Open
We present a case of pulmonary hyalinising granuloma, a rare benign disease of unknown aetiology, diagnosed using lung nodule biopsy. Glucocorticoid treatment reduced the nodule size and was effective for 5 years. However, there was persis…
View article: Quantitative Assessment of Systemic Sclerosis–Related Interstitial Lung Disease via <scp>3D</scp>‐Imaging
Quantitative Assessment of Systemic Sclerosis–Related Interstitial Lung Disease via <span>3D</span>‐Imaging Open
Background and Objective Interstitial lung disease (ILD) is a leading cause of morbidity and mortality in patients with systemic sclerosis (SSc). The disease course of SSc‐related ILD (SSc‐ILD) is heterogeneous, and several risk‐based mode…
View article: First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial
First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial Open
Nivolumab, in addition to carboplatin, paclitaxel, and bevacizumab, remained to demonstrate significantly longer PFS and long-term OS benefit compared with placebo in the first-line treatment of patients with nonsquamous NSCLC. The extende…
View article: Integrin α8 is a useful cell surface marker of alveolar lipofibroblasts
Integrin α8 is a useful cell surface marker of alveolar lipofibroblasts Open
ITGA8+ lung fibroblasts correspond to alveolar lipofibroblasts, but the alveolar niche capacity may be lower than SCA-1+ lung fibroblasts. Further studies are necessary for the functional distinction between lung fibroblast subpopulations.
View article: Severe drug-induced interstitial lung disease after photoimmunotherapy with cetuximab–sarotalocan sodium in a patient with oropharyngeal cancer: A case report
Severe drug-induced interstitial lung disease after photoimmunotherapy with cetuximab–sarotalocan sodium in a patient with oropharyngeal cancer: A case report Open
We report the first case of DIILD caused by CS-PIT. Because cetuximab is a component of CS, CS-PIT has the potential to induce DIILD. Risk assessments and monitoring for DIILD are recommended for patients receiving CS-PIT.
View article: First-line durvalumab plus platinum–etoposide in Japanese patients with extensive-stage small-cell lung cancer
First-line durvalumab plus platinum–etoposide in Japanese patients with extensive-stage small-cell lung cancer Open
First-line EP plus durvalumab was effective and well tolerated in Japanese patients with ES-SCLC in a real-world setting aligning with findings of global studies. This regimen should be considered the standard of care for Japanese patients…
View article: Associations between Immune-related Adverse Events and Prognosis in Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy
Associations between Immune-related Adverse Events and Prognosis in Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy Open
The number of patients with cancer qualifying for treatment with immune checkpoint inhibitors (ICIs) continues to increase, and a clearer understanding of the mechanisms underlying their activity-driven side effects or immune-related adver…
View article: Prognostic value of computed tomography assessment of normal lung volume in upper lobe in idiopathic pleuroparenchymal fibroelastosis
Prognostic value of computed tomography assessment of normal lung volume in upper lobe in idiopathic pleuroparenchymal fibroelastosis Open
This novel method for quantitatively measuring the normal upper-lobe lung volume using three-dimensional computed tomography is useful for assessing disease severity and mortality risk in idiopathic pleuroparenchymal fibroelastosis https:/…
View article: Case of familial interstitial lung disease attributed to ATP-binding cassette transporter 3 gene mutation in identical twins.
Case of familial interstitial lung disease attributed to ATP-binding cassette transporter 3 gene mutation in identical twins. Open
Mutations in ABCA3 can result in surfactant deficiency, leading to respiratory distress syndrome in term neonates, and interstitial lung disease (ILD) in children. Here, we report an extremely rare case of ILD in an identical twin with nov…
View article: 3D-CT-derived lung volumes and mortality risk in patients with fibrotic hypersensitivity pneumonitis
3D-CT-derived lung volumes and mortality risk in patients with fibrotic hypersensitivity pneumonitis Open
Quantitatively measuring standardized LV can help determine disease severity, progression, and mortality risk in patients with fibrotic-HP.
View article: Antifibrotics and mortality in idiopathic pulmonary fibrosis: external validity and avoidance of immortal time bias
Antifibrotics and mortality in idiopathic pulmonary fibrosis: external validity and avoidance of immortal time bias Open
Background and objective Pooled analyses of previous randomized controlled trials reported that antifibrotics improved survival in patients with idiopathic pulmonary fibrosis (IPF), but the results were only based on short-term outcome dat…
View article: Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial
Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial Open
PURPOSE We evaluated the efficacy and safety of antiemetic therapy with olanzapine, a neurokinin-1 receptor antagonist (RA), a 5-hydroxytryptamine-3 (5-HT 3 ) RA, and dexamethasone for preventing chemotherapy-induced nausea and vomiting in…
View article: Investigation of Non-compliance on Specified Clinical Trials Prevented by Clinical Research Coordinators（CRCs）and Trends in Practice After an In-hospital Session on Clinical Research
Investigation of Non-compliance on Specified Clinical Trials Prevented by Clinical Research Coordinators（CRCs）and Trends in Practice After an In-hospital Session on Clinical Research Open
We call cases in which clinical research coordinators (CRCs) prevented non-compliance "good practice" and have been identifying these cases since April 2022. Some instances of serious non-compliance were observed, including those related t…